Distinguished in Angiosarcoma

Dr. Paul K. Marcom

Hematology Oncology
4101 N Roxboro St, 
Durham, NC 
Distinguished in Angiosarcoma
4101 N Roxboro St, 
Durham, NC 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Paul Marcom is a Hematologist Oncology provider in Durham, North Carolina. Dr. Marcom is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Breast Cancer in Men.

His clinical research consists of co-authoring 80 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology Oncology
Licenses
Internal Medicine in NC
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

4101 N Roxboro St, Durham, NC 27704

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: July 09, 2025
Intervention Type: Drug, Other
Study Drugs: Alisertib, Fulvestrant
Study Phase: Phase 2
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)
Enrollment Status: Active_not_recruiting
Publish Date: March 17, 2025
Intervention Type: Drug
Study Drugs: Trastuzumab, Paclitaxel, Trastuzumab emtansine
Study Phase: Phase 2
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2-Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer
Enrollment Status: Completed
Publish Date: February 19, 2025
Intervention Type: Drug
Study Drugs: Paclitaxel, Veliparib, Carboplatin
Study Phase: Phase 3
A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients With Metastatic Breast Cancer
A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients With Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: December 04, 2023
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1b, Single and Multiple Dose, Open-Label Trial of Intravenous GMI-1359 in HR+ Metastatic Breast Cancer Subjects
A Phase 1b, Single and Multiple Dose, Open-Label Trial of Intravenous GMI-1359 in HR+ Metastatic Breast Cancer Subjects
Enrollment Status: Terminated
Publish Date: March 22, 2022
Intervention Type: Drug
Study Drug: GMI-1359
Study Phase: Phase 1
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer
Enrollment Status: Completed
Publish Date: September 14, 2018
Intervention Type: Drug
Study Phase: Phase 2
Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy
Pilot Study of Mirvetuximab Soravtansine (IMGN853) in Folate Receptor Alpha (FRα)-Expressing, Triple Negative Breast Cancer (TNBC) With Residual Disease Post Standard Neoadjuvant Chemotherapy
Enrollment Status: Withdrawn
Publish Date: July 05, 2018
Intervention Type: Drug
Study Phase: Phase 1
Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis
Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis
Enrollment Status: Terminated
Publish Date: February 28, 2018
Intervention Type: Drug
Study Phase: Phase 1
CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer
CSF Pharmacokinetics of Systemic Anti-Cancer Therapies in Patients With Advanced Cancer
Enrollment Status: Terminated
Publish Date: February 28, 2018
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy
Enrollment Status: Withdrawn
Publish Date: June 05, 2017
Intervention Type: Drug
Study Phase: Phase 1
View 9 Less Clinical Trials

80 Total Publications

Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study Experience.
Returning Individual-Level Urgent or Emergent Research Results to Participants: The Project Baseline Health Study Experience.
Journal: American journal of medicine open
Published: September 30, 2024
Similar Doctors
Distinguished in Angiosarcoma
Dr. Mark L. Graham
Hematology Oncology | Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Mark L. Graham
Hematology Oncology | Hematology | Oncology

Wakemed Specialists Group LLC

210 Ashville Ave, 
Cary, NC 
 (22.2 miles away)
919-350-2800
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Mark Graham is a Hematologist Oncology specialist and a Hematologist in Cary, North Carolina. Dr. Graham is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, Bone Marrow Aspiration, and Endoscopy. Dr. Graham is currently accepting new patients.

Hyman B. Muss
Distinguished in Angiosarcoma
Dr. Hyman B. Muss
Hematology Oncology | Hematology | Oncology
Distinguished in Angiosarcoma
Dr. Hyman B. Muss
Hematology Oncology | Hematology | Oncology
143 W Franklin St, 
Chapel Hill, NC 
 (12.7 miles away)
919-966-4131
Languages Spoken:
English
See accepted insurances

Hyman Muss is a Hematologist Oncology specialist and a Hematologist in Chapel Hill, North Carolina. Dr. Muss is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. His top areas of expertise are Breast Cancer, Inflammatory Breast Cancer, Angiosarcoma, and Paget Disease of the Breast.

Gretchen G. Kimmick
Distinguished in Angiosarcoma
Dr. Gretchen G. Kimmick
Hematology Oncology | Oncology
Distinguished in Angiosarcoma
Dr. Gretchen G. Kimmick
Hematology Oncology | Oncology

Duke Health Integrated Practice Inc

1234 Huffman Mill Rd, 
Burlington, NC 
 (33.4 miles away)
919-684-8111
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Gretchen Kimmick is a Hematologist Oncology specialist and an Oncologist in Burlington, North Carolina. Dr. Kimmick is rated as a Distinguished provider by MediFind in the treatment of Angiosarcoma. Her top areas of expertise are Breast Cancer, Paget Disease of the Breast, Angiosarcoma, and Inflammatory Breast Cancer. Dr. Kimmick is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Marcom's expertise for a condition
ConditionClose
View All 11 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile